Fero Industries, Inc. Makes Third Commercial Shipment of Sucanon(R) to Merck & Co., Inc.

CALGARY, AB--(Marketwire - March 31, 2011) - Fero Industries, Inc. (OTCQB: FROI) (OTCBB: FROI) (the “Company”) is pleased to confirm that it has delivered a third shipment of Sucanon® to Merck S.A. de C.V. for distribution in Mexico. The Company is currently preparing the next scheduled Sucanon® shipment for delivery in April to maintain the product’s distribution pipeline.

Each retail package of Sucanon® contains 60 tablets and is the equivalent of a one-month patient supply. Sucanon® is now available in Mexico at over 900 points of sale in major outlets and pharmacy chains.

“This delivery will make a total of three shipments of Sucanon® made in the last 90 days. With each successful delivery, we become more efficient and strengthen our growing tableting and packaging process in Mexico,” said Mr. Luis M. Lopez, MBA., a Director of Fero Industries Inc. and President of Pharmaroth S.A., the Company’s Mexican subsidiary. “Maintaining absolute quality and formulation control while expanding our Sucanon® manufacturing and packaging capabilities will continue to be an essential component of our global growth strategy.”

Sucanon® is approved as an over-the-counter (“OTC”) remedy for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V. (Merck S.A. de C.V. is the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck KGaA.)

Commercial sales of Sucanon® began in January 2011 in Mexico. Mexico has one of the largest and fastest growing diabetic populations in the world, estimated at 15% of the total population. This indicates over 16 million diagnosed cases of diabetes, up seven fold since 1990. Diabetes is now the leading cause of death in Mexico and costs the country more than one-third of its total public health care budget annually.

About Sucanon

Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “Insulin Sensitizers.” Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizer’s lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin. Sucanon® is currently approved for prescription sale in China and Peru. Sucanon® is also been approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V.

For further information regarding Sucanon®, please visit the Fero Industries Inc. website at www.feroindustries.com, email us at info@feroindustries.com, or call toll-free (855) 543-4900.

About Fero Industries Inc.

Fero Industries, Inc. (OTCQB: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and other exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, a treatment for type-2 diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. Fero’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements.

The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors discussed in the Company’s periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov under “Search for Company Filings.”